Paris, July 20th, 2017 – July 20, 2017, Gaithersburg, Md. and Paris – MedImmune, the global biologics research and development arm of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), today announced the renewal of a collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. This collaboration, launched in 2011, has been renewed for the second time, enabling the partnership to extend its work for a total of nine years. The new three-year term is intended to build upon key ongoing research in translational biology and new disease mechanisms.
Since the partnership’s inception, the collaborative research has yielded eighteen scientific publications in peer reviewed journals, as well as eight patent applications. These include several important advances and publications on immuno-oncology and the tumor microenvironment.
Pascale Augé, Chairman of the Executive Management Board of Inserm Transfert said, “This alliance is part of our long-term strategic vision, and—leveraging our collaborative relationship with MedImmune—we are excited to continue advancing cutting edge science from our laboratories. The strength of our projects, where academic and industrial excellence meet, enables us to allow for the best innovation at the highest international standards.”
Yves Levy, Inserm’s Chief Executive Officer, said “Inserm’s leading global rankings in pharmaceutical and biotechnology patent applications is thanks to partnerships like this one with MedImmune (1st in Europe in the pharmaceutical sector; 2nd in Europe in the Biotechnology field). I’m delighted that this ‘win-win’ partnership has been renewed with a commitment to improving human health.”
“MedImmune is pleased to continue its partnership with a premier organization such as Inserm to pursue translational science that can serve as the basis of new discovery for patients in need,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “This relationship exemplifies our commitment to collaborations, which are so critical to creating new avenues for innovative ideas and going where the best science lives.”
Via decision-making governance by a Joint Steering Committee, MedImmune will continue to fund projects to be executed with Inserm for both pre-clinical and clinical research, and will execute other activities to help identify promising approaches to advance drug candidates for patients with unmet medical needs.